The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Boudreau Helen M | Director | Option exercise(M) | 4K | $2.38 | $8K |
| Jul 6, 2026 | Boudreau Helen M | Director | Option exercise(M) | 4K | — | $0 |
| May 19, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 10K | $13.98 | $140K |
| May 19, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 200 | $13.80 | $3K |
| May 18, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 6K | $13.98 | $84K |
| May 15, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 100 | $13.80 | $1K |
| May 15, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 200 | $13.95 | $3K |
| May 13, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 4K | $13.80 | $56K |
| May 13, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 75K | $14.00 | $1.1M |
| May 12, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 800 | $13.83 | $11K |
| May 11, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 5K | $14.00 | $71K |
| May 11, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 25K | $14.00 | $350K |
| May 11, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 20K | $14.00 | $279K |
| May 5, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 35K | $14.00 | $491K |
| May 4, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 4K | $13.90 | $54K |
| May 4, 2026 | ADAR1 Capital Management, LLC | 10% Owner | Buy(P) | 117K | $13.97 | $1.6M |
| Feb 23, 2026 | Lieber Jonathan I | Chief Financial Officer | Sell(S) | 789 | $5.06 | $4K |
| Feb 18, 2026 | Mackay Martin | Director | Grant(A) | 18K | $3.60 | $65K |
| Feb 18, 2026 | Hunt Ronald | Director | Grant(A) | 14K | $3.60 | $51K |
| Feb 18, 2026 | Lieber Jonathan I | Chief Financial Officer | Grant(A) | 3K | — | $0 |
| May 13, 2025 | Mackay Martin | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Liu Hui | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Soteropoulos Paula | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Hopfner Robert Lorne | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Nash Christine A | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Hunt Ronald | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Chung Wendy | Director | Grant(A) | 29K | — | $0 |
| May 13, 2025 | Boudreau Helen M | Director | Grant(A) | 29K | — | $0 |
| Feb 14, 2025 | Lieber Jonathan I | Chief Financial Officer | Grant(A) | 180K | — | $0 |
| Feb 14, 2025 | Ryder Steven | Chief Medical Officer | Grant(A) | 180K | — | $0 |
| Feb 14, 2025 | Uden Stephen | Chief Executive Officer, Director | Grant(A) | 454K | — | $0 |
| Jan 2, 2025 | Liu Hui | Director | Grant(A) | 68K | $0.70 | $47K |
| Jan 2, 2025 | Hopfner Robert Lorne | Director | Grant(A) | 74K | $0.70 | $51K |
| Jan 2, 2025 | Hunt Ronald | Director | Grant(A) | 74K | $0.70 | $51K |
| Jan 2, 2025 | Mackay Martin | Director | Grant(A) | 93K | $0.70 | $65K |
| May 15, 2024 | Chung Wendy | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Hopfner Robert Lorne | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Nash Christine A | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Soteropoulos Paula | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Parmar Kush | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Liu Hui | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Boudreau Helen M | Director | Grant(A) | 17K | — | $0 |
| May 15, 2024 | Hunt Ronald | Director | Grant(A) | 17K | — | $0 |
| Feb 15, 2024 | Ryder Steven | Chief Medical Officer | Grant(A) | 120K | — | $0 |
| Feb 15, 2024 | Lieber Jonathan I | Chief Financial Officer | Grant(A) | 120K | — | $0 |
| Feb 15, 2024 | Mackay Martin | Executive Chairman, Director | Grant(A) | 216K | — | $0 |
| Feb 15, 2024 | Uden Stephen | Chief Executive Officer, Director | Grant(A) | 216K | — | $0 |
| Jan 2, 2024 | Hunt Ronald | Director | Grant(A) | 29K | $1.77 | $51K |
| Jan 2, 2024 | Parmar Kush | Director | Grant(A) | 27K | $1.77 | $48K |
| May 17, 2023 | Chung Wendy | Director | Grant(A) | 12K | — | $0 |
| May 17, 2023 | Hunt Ronald | Director | Grant(A) | 15K | — | $0 |
| May 17, 2023 | Liu Hui | Director | Grant(A) | 15K | — | $0 |
| May 17, 2023 | Soteropoulos Paula | Director | Grant(A) | 15K | — | $0 |
| May 17, 2023 | Hopfner Robert Lorne | Director | Grant(A) | 15K | — | $0 |
| May 17, 2023 | Boudreau Helen M | Director | Grant(A) | 15K | — | $0 |
| May 17, 2023 | Nash Christine A | Director | Grant(A) | 15K | — | $0 |
| May 17, 2023 | Parmar Kush | Director | Grant(A) | 15K | — | $0 |
| Mar 14, 2023 | Lieber Jonathan I | See Remarks | Buy(P) | 5K | $5.21 | $26K |
| Mar 7, 2023 | Schwab Andrew J. | 10% Owner | Sell(S) | 100K | $8.20 | $820K |
| Mar 7, 2023 | Parmar Kush | Director | Sell(S) | 100K | $8.20 | $820K |
| Feb 6, 2023 | Mackay Martin | Chief Executive Officer, Director | Grant(A) | 214K | — | $0 |
| Feb 6, 2023 | Ryder Steven | Chief Medical Officer | Grant(A) | 119K | — | $0 |
| Feb 6, 2023 | Uden Stephen | See Remarks | Grant(A) | 214K | — | $0 |
| Feb 1, 2023 | Lieber Jonathan I | See Remarks | Grant(A) | 240K | — | $0 |
| Jan 3, 2023 | Hunt Ronald | Director | Grant(A) | 11K | — | $0 |
| Jan 3, 2023 | Chung Wendy | Director | Grant(A) | 9K | — | $0 |
| Jan 3, 2023 | Parmar Kush | Director | Grant(A) | 10K | — | $0 |
| Jan 3, 2023 | Liu Hui | Director | Grant(A) | 10K | — | $0 |
| Nov 15, 2022 | Viking Global Opportunities Parent GP LLC | 10% Owner | Buy(P) | 3.3M | $6.00 | $20.0M |
| Aug 1, 2022 | Chung Wendy | Director | Grant(A) | 27K | — | $0 |
| Jun 3, 2022 | 5AM Partners V, LLC | 10% Owner | Sell(S) | 50K | $12.50 | $629K |
| Jun 3, 2022 | 5AM Partners V, LLC | 10% Owner | Sell(S) | 100K | $12.50 | $1.2M |
| Jun 3, 2022 | Parmar Kush | Director, 10% Owner | Sell(S) | 100K | $12.50 | $1.2M |
| Jun 3, 2022 | Parmar Kush | Director, 10% Owner | Sell(S) | 50K | $12.50 | $629K |
| May 24, 2022 | Parmar Kush | Director | Grant(A) | 13K | — | $0 |
| May 24, 2022 | Nash Christine A | Director | Grant(A) | 2K | — | $0 |
| May 24, 2022 | Hopfner Robert Lorne | Director | Grant(A) | 13K | — | $0 |
| May 24, 2022 | Boudreau Helen M | Director | Grant(A) | 13K | — | $0 |
| May 24, 2022 | Hunt Ronald | Director | Grant(A) | 13K | — | $0 |
| May 24, 2022 | Soteropoulos Paula | Director | Grant(A) | 13K | — | $0 |
| May 24, 2022 | Liu Hui | Director | Grant(A) | 2K | — | $0 |
| May 23, 2022 | 5AM Partners V, LLC | 10% Owner | Sell(S) | 34K | $13.00 | $436K |
| May 23, 2022 | 5AM Partners V, LLC | 10% Owner | Sell(S) | 66K | $13.00 | $864K |
| May 23, 2022 | Parmar Kush | Director, 10% Owner | Sell(S) | 66K | $13.00 | $864K |
| May 23, 2022 | Parmar Kush | Director, 10% Owner | Sell(S) | 34K | $13.00 | $436K |
| Apr 4, 2022 | Liu Hui | Director | Grant(A) | 27K | — | $0 |
| Apr 4, 2022 | Nash Christine A | Director | Grant(A) | 27K | — | $0 |
| Mar 21, 2022 | Fryer Jeffrey M | See Remarks | Buy(P) | 3K | $8.04 | $24K |
| Feb 8, 2022 | Parmar Kush | Director | Sell(S) | 140K | $13.05 | $1.8M |
| Feb 8, 2022 | Parmar Kush | Director | Sell(S) | 70K | $13.05 | $920K |
| Feb 8, 2022 | 5AM Ventures V, L.P. | 10% Owner | Sell(S) | 140K | $13.05 | $1.8M |
| Feb 8, 2022 | 5AM Ventures V, L.P. | 10% Owner | Sell(S) | 70K | $13.05 | $920K |
| Feb 7, 2022 | Ryder Steven | Chief Medical Officer | Grant(A) | 62K | — | $0 |
| Feb 7, 2022 | Mackay Martin | Chief Executive Officer, Director | Grant(A) | 62K | — | $0 |
| Feb 7, 2022 | Uden Stephen | See Remarks | Grant(A) | 62K | — | $0 |
| Feb 7, 2022 | Fryer Jeffrey M | Chief Financial Officer | Grant(A) | 62K | — | $0 |
| Jan 19, 2022 | Fryer Jeffrey M | See Remarks | Buy(P) | 1K | $8.70 | $12K |
| Jan 13, 2022 | Uden Stephen | See Remarks | Buy(P) | 807 | $9.62 | $8K |
| Jan 13, 2022 | Uden Stephen | See Remarks | Buy(P) | 4K | $9.06 | $38K |
| Jan 12, 2022 | Uden Stephen | See Remarks | Buy(P) | 5K | $10.55 | $53K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2019-12-30 → 2026-08-06. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for RLYB